CUX1 and neoplasm: In vitro and in vivo, we could show that the p110 CUX1 variant, resulting from proteolytic cleavage of full-length p200 CUX1 by cathepsin L, was active in PDAC and enhanced tumor development in concert with oncogenic Ras.